DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

• Status: Terminated
• Trial end date: 2021-06-04
• Target enrollment: 0
• Participant gender: All

Summary

This is a single center study for the donation of HCV-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Antiviral Agents; Sofosbuvir

Criteria

Inclusion Criteria:

• Recipient is Age ≥ 18 years

• Met MGH transplant center criteria, listed for liver transplant

• HCV naïve

• Able to sign informed consent

Exclusion Criteria:

• Pregnant or nursing (lactating) women

• HIV positivity

• Need for dual organ transplant

• Any contra-indication to liver transplantation per center protocol